Breaking News
Sort by:
Top Post
Roche’s Tecentriq Plus Avastin Reduced Risk of Cancer Returning in People with Certain Types of Adjuvant Liver Cancer in a Phase III Study
Roche has announced new data from the Phase III IMbrave050 study that show Tecentriq (atezolizumab) […]
World’s First Chemo Drone Delivery Announced on NHS Birthday
NHS cancer patients will be the first in the world to benefit from chemotherapy delivered […]
Faeth Therapeutics Raises $47 Million to Advance Clinical Trials and Feed the Fight Against Cancer
Faeth Therapeutics, a cancer metabolism company, today announced the closing of a $47 million Series A round […]
New Phase III Data Show Novartis Tislelizumab Significantly Extended Median Overall Survival by More Than 6 Months in First-line Advanced Esophageal Cancer in Combination With Chemotherapy
Today Novartis announced results from the Phase III RATIONALE 306 trial showing tislelizumab plus chemotherapy […]
GSK Completes Acquisition of Sierra Oncology
GSK plc (LSE/NYSE: GSK) today announced it has completed the acquisition of Sierra Oncology, Inc. […]
Revolution in Care of Leukaemia as New Treatment Drug Approved for Cancer Patients
The charity Leukaemia Care today welcomes the news from the National Institute for Health and Care Excellence […]
The PanDIA-1 Study, for Early Detection of Pancreatic Cancer in Newly Onset Type 2 Diabetics, Moves Into Next Phase
Immunovia today announced the PanDIA-1 study for the early detection of pancreatic cancer in newly […]
Roche Launches New BenchMark ULTRA PLUS System for Cancer Diagnostics Enabling Timely, Targeted Patient Care
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the BenchMark ULTRA PLUS system, its […]
INOVIO Appoints Dr. Michael Sumner, MB BS, MBA as Chief Medical Officer
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect […]
Degron Therapeutics Co-Founder Provides New Strategy for Molecular Glue in Tumor Immunotherapy
Degron Therapeutics (“Degron”), a biotechnology company developing a new class of small-molecule medicines that target […]
Antengene Announces Clinical Trial Collaboration with BeiGene to Evaluate Selinexor in Combination with Tislelizumab in T and NK-Cell Lymphoma
Antengene Corporation Limited (“Antengene“ SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more